These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 10969209

  • 1. [JM216, an orally active platine derivative].
    Lansiaux A, Bailly C.
    Bull Cancer; 2000 Jul; 87(7-8):531-6. PubMed ID: 10969209
    [No Abstract] [Full Text] [Related]

  • 2. Metabolism, protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products.
    Raynaud FI, Boxall FE, Goddard P, Barnard CF, Murrer BA, Kelland LR.
    Anticancer Res; 1996 Jul; 16(4A):1857-62. PubMed ID: 8712713
    [Abstract] [Full Text] [Related]

  • 3. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts.
    Vaisman A, Varchenko M, Umar A, Kunkel TA, Risinger JI, Barrett JC, Hamilton TC, Chaney SG.
    Cancer Res; 1998 Aug 15; 58(16):3579-85. PubMed ID: 9721864
    [Abstract] [Full Text] [Related]

  • 4. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
    Samimi G, Kishimoto S, Manorek G, Breaux JK, Howell SB.
    Cancer Chemother Pharmacol; 2007 Feb 15; 59(3):301-12. PubMed ID: 16770583
    [Abstract] [Full Text] [Related]

  • 5. DNA adducts of cisplatin, transplatin and platinum-intercalating drugs.
    Leng M, Brabec V.
    IARC Sci Publ; 1994 Feb 15; (125):339-48. PubMed ID: 7806323
    [No Abstract] [Full Text] [Related]

  • 6. Preclinical antitumor activity of the oral platinum analog satraplatin.
    Wosikowski K, Lamphere L, Unteregger G, Jung V, Kaplan F, Xu JP, Rattel B, Caligiuri M.
    Cancer Chemother Pharmacol; 2007 Sep 15; 60(4):589-600. PubMed ID: 17541592
    [Abstract] [Full Text] [Related]

  • 7. Platinum(IV) complex with adamantylamine as nonleaving amine group: synthesis, characterization, and in vitro antitumor activity against a panel of cisplatin-resistant cancer cell lines.
    Zák F, Turánek J, Kroutil A, Sova P, Mistr A, Poulová A, Mikolin P, Zák Z, Kasná A, Záluská D, Neca J, Sindlerová L, Kozubík A.
    J Med Chem; 2004 Jan 29; 47(3):761-3. PubMed ID: 14736257
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cisplatinum and transplatinum complexes with benzyliminoether ligands; synthesis, characterization, structure-activity relationships, and in vitro and in vivo antitumor efficacy.
    Sbovata SM, Bettio F, Mozzon M, Bertani R, Venzo A, Benetollo F, Michelin RA, Gandin V, Marzano C.
    J Med Chem; 2007 Sep 20; 50(19):4775-84. PubMed ID: 17713897
    [Abstract] [Full Text] [Related]

  • 11. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
    Marzano C, Bettio F, Baccichetti F, Trevisan A, Giovagnini L, Fregona D.
    Chem Biol Interact; 2004 Jun 30; 148(1-2):37-48. PubMed ID: 15223355
    [Abstract] [Full Text] [Related]

  • 12. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma.
    Zamboni WC, Gervais AC, Egorin MJ, Schellens JH, Zuhowski EG, Pluim D, Joseph E, Hamburger DR, Working PK, Colbern G, Tonda ME, Potter DM, Eiseman JL.
    Cancer Chemother Pharmacol; 2004 Apr 30; 53(4):329-36. PubMed ID: 14673619
    [Abstract] [Full Text] [Related]

  • 13. Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status.
    Martelli L, Di Mario F, Botti P, Ragazzi E, Martelli M, Kelland L.
    Biochem Pharmacol; 2007 Jun 30; 74(1):20-7. PubMed ID: 17466278
    [Abstract] [Full Text] [Related]

  • 14. Platinum(II) compounds with chelating ligands based on pyridine and pyrimidine: synthesis, characterizations, DFT calculations, cytotoxic assays and binding to a DNA model base.
    Roy S, Westmaas JA, Buda F, Reedijk J.
    J Inorg Biochem; 2009 Sep 30; 103(9):1278-87. PubMed ID: 19656572
    [Abstract] [Full Text] [Related]

  • 15. Proapoptotic effect on normal and tumor intestinal cells of cytostatic drugs with enterohepatic organotropism.
    Monte MJ, Ballestero MR, Briz O, Perez MJ, Marin JJ.
    J Pharmacol Exp Ther; 2005 Oct 30; 315(1):24-35. PubMed ID: 15985617
    [Abstract] [Full Text] [Related]

  • 16. In vitro and in vivo antitumor activity of the novel trinuclear platinum complex BBR 3464 in neuroblastoma.
    Riccardi A, Meco D, Ferlini C, Servidei T, Carelli G, Segni G, Manzotti C, Riccardi R.
    Cancer Chemother Pharmacol; 2001 Jun 30; 47(6):498-504. PubMed ID: 11459202
    [Abstract] [Full Text] [Related]

  • 17. Synthesis and characterization of platinum(II) oxadiazoline complexes and their in vitro antitumor activity in platinum-sensitive and -resistant cancer cell lines.
    Coley HM, Sarju J, Wagner G.
    J Med Chem; 2008 Jan 10; 51(1):135-41. PubMed ID: 18072719
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Platinum complexes as potential antineoplastic drugs].
    Kuduk-Jaworska J.
    Postepy Hig Med Dosw; 1984 Jan 10; 38(3):281-322. PubMed ID: 6398870
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.